Biocon eyes US and Europe markets

India’s largest biotechnology company Biocon is planning to tap the potential of biosimilars in the regulated markets of the US and Europe, besides taking Insugen, its own version of insulin, to the global markets in a big way. The launch of biosimilars in the US and Europe is planned over the next 2 or 3 years, by which time proper laws would evolve for biosimilars in these regions. Biocon is in the process of registering with the regulatory authorities in the developed markets for the launch of Insugen. Insugen has already been licensed to a US market and to Bayer for China.